SCHEMBL9909202

SCHEMBL9909202

COC(=O)c1ccc2nccc(-c3ccccc3OC)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.51
ALOX15 P16050 1/20 0.51
CHUK O15111 1/20 0.47
INSR P06213 1/20 0.47
MAPK8 P45983 1/20 0.47
CAMKK2 Q96RR4 1/20 0.47
CCNB2 O95067 1/20 0.46
CDK1 P06493 1/20 0.46
CCNB1 P14635 1/20 0.46
GSK3A P49840 1/20 0.46
GSK3B P49841 1/20 0.46
CDK5 Q00535 1/20 0.46
CDK5R1 Q15078 1/20 0.46
CCNB3 Q8WWL7 1/20 0.46
SCN9A Q15858 3/20 0.46
GCGR P47871 1/20 0.46
TGFBR1 P36897 1/20 0.45
KDM1A O60341 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909213 0.89 KDM4C (0.46) CHUKINSRMAPK8CAMKK2CCNB2
SCHEMBL9907404 0.86 ALOX15 (0.52) HTTALOX15TGFBR1ALDH1A1TSHR
SCHEMBL6301162 0.84 ALOX15 (0.57) HTTALOX15GCGRTGFBR1MAPT
SCHEMBL9907325 0.83 ALOX15 (0.55) HTTALOX15CAMKK2TGFBR1ALDH1A1
SCHEMBL9909209 0.82 HTR5A (0.49) CHUKINSRMAPK8CAMKK2GCGR
SCHEMBL9907341 0.82 HTT (0.48) HTTALOX15TGFBR1ALDH1A1TSHR
SCHEMBL9909186 0.82 ALOX15 (0.48) HTTALOX15CCNB2CDK1CCNB1
SCHEMBL9909208 0.82 SCN9A (0.51) HTTALOX15SCN9ATGFBR1CCNT1
SCHEMBL9907339 0.81 ALOX15 (0.49) HTTALOX15TGFBR1ALDH1A1TSHR
SCHEMBL9907393 0.80 HTT (0.51) HTTALOX15TGFBR1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2012-06-13 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E HTT 970/4885ALOX15 1101/4885CHUK 2224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.